These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28259950)

  • 21. Proteomic analysis of acute promyelocytic leukemia: PML-RARalpha leads to decreased phosphorylation of OP18 at serine 63.
    Zada AA; Geletu MH; Pulikkan JA; Müller-Tidow C; Reddy VA; Christopeit M; Hiddemann WD; Behre HM; Tenen DG; Behre G
    Proteomics; 2006 Nov; 6(21):5705-19. PubMed ID: 17001604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA.
    Hanke M; Dubois J; Kausch I; Petkovic S; Sczakiel G
    PLoS One; 2020; 15(7):e0229193. PubMed ID: 32614890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
    Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
    Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
    Mistry SJ; Bank A; Atweh GF
    Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics.
    Marklund U; Larsson N; Gradin HM; Brattsand G; Gullberg M
    EMBO J; 1996 Oct; 15(19):5290-8. PubMed ID: 8895574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined therapeutic effects of vinblastine and Astragalus saponins in human colon cancer cells and tumor xenograft via inhibition of tumor growth and proangiogenic factors.
    Auyeung KK; Law PC; Ko JK
    Nutr Cancer; 2014; 66(4):662-74. PubMed ID: 24660995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1.
    Wittmann T; Bokoch GM; Waterman-Storer CM
    J Biol Chem; 2004 Feb; 279(7):6196-203. PubMed ID: 14645234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.
    Kolomeichuk SN; Terrano DT; Lyle CS; Sabapathy K; Chambers TC
    FEBS J; 2008 Apr; 275(8):1889-99. PubMed ID: 18341588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells.
    Brattsand G; Roos G; Marklund U; Ueda H; Landberg G; Nånberg E; Sideras P; Gullberg M
    Leukemia; 1993 Apr; 7(4):569-79. PubMed ID: 8464235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
    Aoyama M; MacIsaac D; Bukowski RM; Ganapathi MK
    Clin Cancer Res; 1998 Apr; 4(4):1039-45. PubMed ID: 9563900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
    Alli E; Bash-Babula J; Yang JM; Hait WN
    Cancer Res; 2002 Dec; 62(23):6864-9. PubMed ID: 12460900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
    Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association.
    Larsson N; Segerman B; Gradin HM; Wandzioch E; Cassimeris L; Gullberg M
    Mol Cell Biol; 1999 Mar; 19(3):2242-50. PubMed ID: 10022911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin.
    Kang JH; Kang HS; Kim IK; Lee HY; Ha JH; Yeo CD; Kang HH; Moon HS; Lee SH
    Exp Biol Med (Maywood); 2015 Nov; 240(11):1416-25. PubMed ID: 25716014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18-->e mutation in leukemic cells.
    Holmfeldt P; Brännström K; Stenmark S; Gullberg M
    Mol Biol Cell; 2006 Jul; 17(7):2921-30. PubMed ID: 16624860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas.
    Chen G; Wang H; Gharib TG; Huang CC; Thomas DG; Shedden KA; Kuick R; Taylor JM; Kardia SL; Misek DE; Giordano TJ; Iannettoni MD; Orringer MB; Hanash SM; Beer DG
    Mol Cell Proteomics; 2003 Feb; 2(2):107-16. PubMed ID: 12644570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo.
    Zhang D; Qiu L; Jin X; Guo Z; Guo C
    Mol Cancer Res; 2009 Jul; 7(7):1139-49. PubMed ID: 19584264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells.
    Kawamura KI; Grabowski D; Weizer K; Bukowski R; Ganapathi R
    Br J Cancer; 1996 Jan; 73(2):183-8. PubMed ID: 8546904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.